Brokerages forecast that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will post sales of $5.16 million for the current quarter, Zacks reports. Four analysts have provided estimates for BioCryst Pharmaceuticals’ earnings. The highest sales estimate is $7.84 million and the lowest is $2.91 million. BioCryst Pharmaceuticals posted sales of $7.76 million in the same quarter last year, which suggests a negative year-over-year growth rate of 33.5%. The firm is scheduled to issue its next earnings report on Monday, November 6th.

On average, analysts expect that BioCryst Pharmaceuticals will report full-year sales of $5.16 million for the current financial year, with estimates ranging from $18.36 million to $29.58 million. For the next fiscal year, analysts anticipate that the company will post sales of $25.36 million per share, with estimates ranging from $16.75 million to $34.66 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.02. BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The business had revenue of $3.10 million for the quarter, compared to analyst estimates of $5.79 million. During the same quarter in the previous year, the company posted ($0.22) earnings per share. The business’s revenue for the quarter was down 35.4% on a year-over-year basis.

BCRX has been the topic of a number of recent analyst reports. Zacks Investment Research lowered BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 8th. BidaskClub raised BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, May 19th. ValuEngine raised BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, August 28th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the stock. BioCryst Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $8.00.

WARNING: This piece of content was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/brokerages-anticipate-biocryst-pharmaceuticals-inc-bcrx-will-announce-quarterly-sales-of-5-16-million/1538050.html.

A number of large investors have recently modified their holdings of BCRX. UBS Asset Management Americas Inc. acquired a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth $392,000. Swiss National Bank increased its stake in shares of BioCryst Pharmaceuticals by 18.7% in the first quarter. Swiss National Bank now owns 114,300 shares of the biotechnology company’s stock worth $960,000 after buying an additional 18,000 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of BioCryst Pharmaceuticals by 6.8% in the first quarter. Bank of New York Mellon Corp now owns 361,289 shares of the biotechnology company’s stock worth $3,035,000 after buying an additional 23,072 shares during the last quarter. Emory University acquired a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth $3,153,000. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of BioCryst Pharmaceuticals by 23.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 333,373 shares of the biotechnology company’s stock worth $2,801,000 after buying an additional 62,792 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Shares of BioCryst Pharmaceuticals (BCRX) opened at 5.00 on Friday. The company’s market capitalization is $402.14 million. The stock has a 50 day moving average price of $4.88 and a 200-day moving average price of $6.13. BioCryst Pharmaceuticals has a 52 week low of $3.75 and a 52 week high of $9.25.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.